User:Estelle Metzger/Sandbox

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 3: Line 3:
Some study to find a treatment for the Parkinson's disease are focused on LRRK2. Indeed, mutations in LRRK2, which increases its kinase activity, are found in case of Parkinson’s disease. Thus, a kinase inhibitor for LRRK2 would be an interesting thetapeutic target.
Some study to find a treatment for the Parkinson's disease are focused on LRRK2. Indeed, mutations in LRRK2, which increases its kinase activity, are found in case of Parkinson’s disease. Thus, a kinase inhibitor for LRRK2 would be an interesting thetapeutic target.
-
Thanks to the similarity between LRRK2 and Roco4 from the ''Dictyostelium'', Roco4 is used in studies with a view to finding that inhibitor. One of the candidates to inhibit this activity is LRRK2-IN-1<ref name="Bernd">doi: 10.1021/jm5018779</ref>.
+
Thanks to the similarity between LRRK2 and Roco4 from the ''Dictyostelium'', Roco4 is used in studies with a view to finding that inhibitor. One of the candidates to inhibit this activity is LRRK2-IN-1.<ref name="Bernd">doi: 10.1021/jm5018779</ref>
Line 23: Line 23:
This involves autophosphorylation of some residues in the activation loop. . Autophosphorylation not only results in the reorientation of the activation loop, but often also alters ATP binding and/or interaction with substrates. (Huse and Kuriyan 2002 kornev). In Roco4 kinase, there are four phosphorylation sites in the activation loop : Ser1181, Ser1184, Ser1187, and Ser1189.
This involves autophosphorylation of some residues in the activation loop. . Autophosphorylation not only results in the reorientation of the activation loop, but often also alters ATP binding and/or interaction with substrates. (Huse and Kuriyan 2002 kornev). In Roco4 kinase, there are four phosphorylation sites in the activation loop : Ser1181, Ser1184, Ser1187, and Ser1189.
-
The structure of ''Dictyostelium'' Roco4 kinase in complex with the LRRK2 inhibitor H1152 allows us to see that Roco4 and other Roco family proteins are essential for the optimization of the current, and identification of new LRRK2 kinase inhibitor. To have a Roco4 protein which have an active site resembling human LRRK2, researchers use a ''Dictyostelium'' Roco4 mutant (F1107L and F1161L) which is called humanized Roco4<ref name="Bernd"/>.
+
The structure of ''Dictyostelium'' Roco4 kinase in complex with the LRRK2 inhibitor H1152 allows us to see that Roco4 and other Roco family proteins are essential for the optimization of the current, and identification of new LRRK2 kinase inhibitor. To have a Roco4 protein which have an active site resembling human LRRK2, researchers use a ''Dictyostelium'' Roco4 mutant (F1107L and F1161L) which is called humanised Roco4.<ref name="Bernd"/>
Line 30: Line 30:
<scene name='75/751216/Lrrk2-in-1/1'>LRRK2-IN-1</scene> is a type 1 inhibitor. It is the first identified LRRK2-specific inhibitor, which is now a common tool compound for the LRRK2 research community. LRRK2-IN-1 has a 2-amino-5,11- dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine-6(11H)-one scaffold.
<scene name='75/751216/Lrrk2-in-1/1'>LRRK2-IN-1</scene> is a type 1 inhibitor. It is the first identified LRRK2-specific inhibitor, which is now a common tool compound for the LRRK2 research community. LRRK2-IN-1 has a 2-amino-5,11- dimethyl-5H-benzo[e]pyrimido[5,4-b][1,4]diazepine-6(11H)-one scaffold.
The function is of LRRK2-In-1 is to dephosphorylate LRRK2 residues Ser910 and Ser935 in the kidney, but not in the brain. This compound is not capable of crossing the blood-brain barrier.
The function is of LRRK2-In-1 is to dephosphorylate LRRK2 residues Ser910 and Ser935 in the kidney, but not in the brain. This compound is not capable of crossing the blood-brain barrier.
-
The structure of LRRK2-In-1 does not stabilize the active conformation. Indeed, the activation loop is poorly resolved indicating that it is flexible. Moreover, it presents a closure of the glycine-rich loop in the inhibitor structure <ref name="Bernd"/>.
+
The structure of LRRK2-In-1 does not stabilize the active conformation. Indeed, the activation loop is poorly resolved indicating that it is flexible. Moreover, it presents a closure of the glycine-rich loop in the inhibitor structure.<ref name="Bernd"/>
Line 39: Line 39:
== Relevance ==
== Relevance ==
-
LRRK2, for leucine-rich repeat serin/thereonin kinase 2, is a protein from the Roco family of G-proteins. It takes part in divers pathway such as synaptic vesicule trafficking, retrograde trafficking pathway for recycling protein or the CaMKK/AMPK pathway. Its importance comes from the fact that its susspetced to have a role in the phosphorylation of a central protein in the Parkinson’s disease. (Uniprot) Indeed, mutation associated with Parkinson Disease can be found in asmost every domains of LRRK2. For techrapeutic research Rocco4 from the Dictyostelium was mutated, especially in the active site, in order to mime LRRK2<ref name="Bernd"/>.
+
LRRK2, for leucine-rich repeat serin/thereonin kinase 2, is a protein from the Roco family of G-proteins. It takes part in divers pathway such as synaptic vesicule trafficking, retrograde trafficking pathway for recycling protein or the CaMKK/AMPK pathway. Its importance comes from the fact that its susspetced to have a role in the phosphorylation of a central protein in the Parkinson’s disease. (Uniprot) Indeed, mutation associated with Parkinson Disease can be found in asmost every domains of LRRK2. For techrapeutic research Rocco4 from the Dictyostelium was mutated, especially in the active site, in order to mime LRRK2.<ref name="Bernd"/>
== Disease ==
== Disease ==
The Parkinson’s disease (PD) is a neurodegenerative disorder that is associated with resting termor, bradykinesia, rigidity and postural instability. (Uniprot) This is the second most common neurodegenerative disorder, which is affecting 2% of the population above 65 years<ref name="Bernd"/>.
The Parkinson’s disease (PD) is a neurodegenerative disorder that is associated with resting termor, bradykinesia, rigidity and postural instability. (Uniprot) This is the second most common neurodegenerative disorder, which is affecting 2% of the population above 65 years<ref name="Bernd"/>.
-
Two types of Parkinson’s disease existe, the heditary or the sporadic also called idiopathic. LRRK2 mutations can be found in almost its every domains for both types. The most important mutation is the G2019S, which is located on the kinase domain. It stabilise the domains, thus leading to an indresed kinase activity of 2 to 4 fold. That’s why a treatment stategy would be to develop a kinase inhibitor in order to counter it<ref name="Bernd"/>.
+
Two types of Parkinson’s disease existe, the heditary or the sporadic also called idiopathic. LRRK2 mutations can be found in almost its every domains for both types. The most important mutation is the G2019S, which is located on the kinase domain. It stabilise the domains, thus leading to an indresed kinase activity of 2 to 4 fold. That’s why a treatment stategy would be to develop a kinase inhibitor in order to counter it.<ref name="Bernd"/>
-
The use of roco4, permited to learn that the G2019S mutation is the results of an additional hydrogen bound between Ser2019 ( Ser1179 in Roco4) and Gln1918 (Arg1077 in Roco4)<ref name="Bernd"/>.
+
The use of roco4, permited to learn that the G2019S mutation is the results of an additional hydrogen bound between Ser2019 ( Ser1179 in Roco4) and Gln1918 (Arg1077 in Roco4).<ref name="Bernd"/>
</StructureSection>
</StructureSection>
== References ==
== References ==
<references/>
<references/>

Revision as of 15:18, 26 January 2017

Humanized Roco4 bound to LRRK2-IN-1

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Gilsbach BK, Messias AC, Ito G, Sattler M, Alessi DR, Wittinghofer A, Kortholt A. Structural Characterization of LRRK2 Inhibitors. J Med Chem. 2015 May 1. PMID:25897865 doi:http://dx.doi.org/10.1021/jm5018779
  2. Gilsbach BK, Kortholt A. Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci. 2014 May 5;7:32. doi: 10.3389/fnmol.2014.00032. eCollection, 2014. PMID:24847205 doi:http://dx.doi.org/10.3389/fnmol.2014.00032

Proteopedia Page Contributors and Editors (what is this?)

Estelle Metzger

Personal tools